Longitudinal Serological Response to Sars-COV-2 in Patients Affected By Hematologic Diseases

Introduction. Covid-19 patients (pts) with hematologic malignancies have a severe prognosis with mortality rates around 40%, particularly when on active treatment (Cattaneo et al, Cancer, in press). However, the long-term prognosis and persistence of specific immune responses among those who survive...

Descripción completa

Detalles Bibliográficos
Autores principales: Cattaneo, Chiara, Cancelli, Valeria, Pagani, Chiara, Tucci, Alessandra, Rossi, Giuseppe, Imberti, Luisa, Sottini, Alessandra, Dobbs, Kerry, Shaw, Elana, Notarangelo, Luigi D., Cohen, Jeffrey, Burbelo, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
203.Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330366/
http://dx.doi.org/10.1182/blood-2020-141355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330366/
http://dx.doi.org/10.1182/blood-2020-141355

Ejemplares similares